Nasdaq

Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting

CAMBRIDGE, MA / ACCESSWIRE / May 19, 2023 / Moderna,Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, reported on interim data from the Phase 1/2 ...
Nasdaq

Moderna Receives FDA Fast Track Designation for Propionic Acidemia Program (mRNA-3927)

mRNA-3927 uses the same proprietary LNP formulation as mRNA-1944 (antibody against Chikungunya virus) and mRNA-3704 (methylmalonic acidemia) “Fast Track designation underscores the urgent need for a ...
Monthly Prescribing Reference

Investigational mRNA Therapeutic Fast-Tracked for Propionic Acidemia

Cholesterol bloodstream The FDA has granted Fast Track designation to mRNA-3927 (Moderna), an investigational mRNA therapeutic for propionic acidemia. The Food and Drug Administration (FDA) has ...
AZ Central

Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)

Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition to commercial and sales milestones and tiered royalties on net sales CAMBRIDGE, MA / ...
Morningstar

Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)

CAMBRIDGE, MA / ACCESS Newswire / January 29, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced a strategic collaboration with Recordati to advance Moderna's investigational propionic acidemia (PA) ...
KXAN

Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting

After completing enrollment in 5 dose cohorts, and with no dose-limiting safety signals observed to date by the independent DSMB, the Phase 1/2 trial of mRNA-3927 advances to the dose-expansion phase ...